Compares mezigdomide with pomalidomide in relapsed or refractory multiple myeloma
Tests mezigdomide, bortezomib and dexamethasone against pomalidomide combination in adults with myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Key facts
- Where
- Ahmedabad, Belagavi, Gurugram, Ludhiana, Madurai, Mumbai, Puducherry, and Varanasi, IndiaSee the 8 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding to treatment. They must have had 1 to 3 earlier treatments, including lenalidomide.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Relapsed or refractory multiple myeloma with measurable disease (M-protein ≥ 0.5 g/dL in blood, or ≥ 200 mg per 24-hour urine, or serum free light chain > 100 mg/L with an abnormal kappa/lambda ratio)
- Earlier treatment
- Must have had 1 to 3 earlier lines of myeloma treatment, with at least a minimal response to one of them. Must have had prior lenalidomide. Must not have had mezigdomide or pomalidomide.
Main reasons for not taking part
- Disease got worse during, or within 60 days of, a proteasome inhibitor (some exceptions apply)
- Earlier bortezomib treatment did not bring at least a minimal response, or was stopped because of side effects
- Earlier treatment with mezigdomide or pomalidomide
- Other criteria set by the study protocol
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which of these best describes your myeloma treatment so far?
- Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
- Has a doctor told you that your myeloma can be measured in your blood or urine tests?
Source: NCT05519085, who can take part
Where in India
- HCG Aastha Cancer CentreAhmedabad, IndiaTaking people
- KLES Dr. Prabhakar Kore Hospital & M.R.CBelagavi, IndiaTaking people
- Marengo Asia Hospitals GurugramGurugram, IndiaTaking people
- Christian Medical College & HospitalLudhiana, IndiaTaking people
- MaduraiMadurai, IndiaNo longer taking part
- Mumbai Oncocare Centre - NanachowkMumbai, IndiaTaking people
- Jawaharlal Institute of postgraduate medical education and researchPuducherry, IndiaTaking people
- VaranasiVaranasi, IndiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Celgene
- Trial code
- NCT05519085
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.Read full original descriptionShow less
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Inclusion: Participant has documented diagnosis of MM and measurable disease, defined as any of the following:; M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or; M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP); For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio; Participants received 1 to 3 prior lines of antimyeloma therapy; Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.
Exclusion: Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:; Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded; Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded; For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity; Participant has had prior treatment with mezigdomide or pomalidomide; Other protocol-defined Inclusion/Exclusion criteria apply.